Morning Read: Report tracks steep drug price increases by pharma companies
Also, an outbreak of VIP syndrome at hospitals, fashionable prosthetics and Samsung's advancement of biosimilar drug for rheumatoid arthritis.
Valeant looking for new CEO as Pearson steps down – desperation calls for change?
Today it was announced that Valeant CEO Mike Pearson is officially walking away from his position with the pharmaceutical company, though he will stay on board until a replacement is established.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The pharmaceutical industry must go digital. Here’s why – and how.
The digitization of healthcare is changing the way physicians practice, and patients receive treatment. The pharmaceutical industry is behind the times in digital medicine - but must change quickly to adapt to the times.
Business lessons from Valeant CEO Michael Pearson (video)
Maybe Martin Shkreli will have a bit of a breather now that Valeant's Michael Pearson is keeping the hot seat warm.
Morning Read: America hates Big Pharma again
Plus, poverty said to be a factor in readmissions, CDC has permanent associate director of lab safety and women called clueless about women's health.
From the Salesforce Health Cloud news to a Big Pharma video game: 5 must-read stories from MedCity News this week
There was a lot of big Salesforce Health Cloud news this week, along with insights on treating depression and a new video game that simulates what it's like to work in Big Pharma.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Run your own virtual pharmaceutical company with new video game – ethical decision-making optional
Anyone can have their hand in the ethical minefield of Big Pharma with this new sims game.
Do drug manufacturers have it even harder than rocket scientists?
Even as the understanding of science continues to progress, that doesn't necessarily mean it makes things easier for drug manufacturers.
21st Century Cures: Rare disease incentives for pharma will cost the government $869M
There's a provision in the 21st Century Cures bill to incentivize pharmaceutical companies to churn out new rare disease therapies - but it comes with a price.
Bristol-Myers Squibb cuts virology R&D, focusing on cancer
Bristol-Myers Squibb's move largely impacts its early work in hepatitis B and HIV therapies, though it won't affect the virology therapies currently on the market.
BioLabs Pegasus Park Cultivates Life Science Ecosystem
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
Debate: To what extent should doctors work with big pharma?
There's been a lot of criticism toward physician relationships with big pharma. But have we gone too far? A brewing academic debate examines this issue.
Drug development costs: Is $2.6B correct? Big pharma may profit from inflated estimates.
Drug costs are astronomical – this we know. But we don’t have a transparent, informed way of calculating – or understanding – the true costs of drug development, argued Dr. Jerry Avorn, a professor of pharmacoeconomics at Harvard University, in this week’s New England Journal of Medicine. And this ignorance may be helping big pharma inflate the price of drugs. He […]
John Oliver breaks down the influence pharma reps have on doctors (sometimes free lunch is all it takes)
Anyone who watches TV knows pharmaceutical ads dominate commercial breaks and leave many wondering, “Well, I am just sitting on the couch eating a sandwich, and I don’t feel like getting up, does that make me depressed?” Companies clearly want to appeal to consumers, in fact they spend an estimated $4 billion a year in […]
Pre-Hatch-Waxman paper NDAs could get a break from branded Rx drug fee
By Alan M. Kirschenbaum – Beginning with CY 2011, Section 9008 of the Patient Protection and Affordable Care Act (“ACA”) has imposed an annual fee on manufacturers and importers of “branded prescription drugs.” The global 2014 fee for all manufacturers...
GSK’s new web effort hopes to help patients better cope with COPD
GlaxoSmithKline, better known as GSK, has launched a new web effort aimed at providing both information and inspiration for people with chronic obstructive pulmonary disease, in what the company says is arguably the most engaging platform in the marketplace. The rollout of the new COPD.com goes beyond what was previously offered, certainly by GSK but possibly […]